On July 31, Express Scripts identified new formulary exclusions that will go into effect on January 1, 2018.  For example, Amgen’s rG-CSF product, NEUPOGEN, will be excluded in favor of Teva’s rG-CSF product, GRANIX, and Sandoz’s biosimilar, ZARXIO.  Express Scripts has not explained, however, what the reimbursement level will be for GRANIX and ZARXIO, or how much a patient will have to pay for them as compared to the cost of NEUPOGEN.

Express Scripts noted that “[t]he full list of excluded products [for 2018] will be available on or before September 15, 2017.”

Stay tuned to Big Molecule Watch for further updates.